BLUE Stock Analysis
BL
Uncovered
bluebird bio Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. The company is headquartered in Somerville, Massachusetts and currently employs 518 full-time employees. The company went IPO on 2013-06-19. The firm is principally focused on researching, developing and commercializing gene therapies for genetic diseases. The Company’s gene therapy programs in genetic diseases include programs for B-thalassemia; LentiGlobin product candidate as a treatment for sickle cell disease (SCD), and elivaldogene autotemcel (eli-cel) as a treatment for cerebral adrenoleukodystrophy (CALD). The company is using a lentiviral vector (LVV) platform, it custom designs each of its therapies to address the underlying cause of disease. The firm is developing lovotibeglogene autotemcel (lovo-cel) as a one-time treatment for patients with SCD, a genetic disease caused by a single mutation in the B-globin gene that leads to the production of abnormal sickle hemoglobin (HbS). The BLA for betibeglogene autotemcel (beti-cel) is for B-thalassemia in patients who receive regular red blood cell (RBC) transfusions.